Abstract
Cholinesterase inhibitors and memantine are widely used for the treatment of Alzheimer disease (AD) and other non-AD dementia worldwide. Since 2000, large scale prospective random control studies using meta-analysis have provided clinical evidence for the use of these drugs in AD and non-AD dementia. Here, we review these reports, including those on other drugs and newly developed drugs, which provide detailed clinical information for the daily management of dementia.
MeSH terms
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / etiology
-
Alzheimer Disease / prevention & control
-
Amyloid beta-Peptides
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cholinesterase Inhibitors / therapeutic use*
-
Clioquinol / analogs & derivatives
-
Drug Design*
-
Excitatory Amino Acid Antagonists / therapeutic use
-
Flurbiprofen
-
Indoles
-
Memantine / therapeutic use
-
Meta-Analysis as Topic
-
Randomized Controlled Trials as Topic
Substances
-
AN-1792
-
Amyloid beta-Peptides
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cholinesterase Inhibitors
-
Excitatory Amino Acid Antagonists
-
Indoles
-
PBT2 compound
-
tarenflurbil
-
Flurbiprofen
-
Clioquinol
-
latrepirdine
-
Memantine